Last Placement

BOTANIX PHARMACEUTICALS LTD

Botanix Pharma aims to develop​ next-generation therapeutics for the treatment of serious skin diseases. The company's mission is to improve the lives of patients battling acne, psoriasis and atopic dermatitis, by providing new treatment options for conditions that currently are inadequately addressed or are treated with therapeutics that are burdened with side effects profiles.

The company is developing the potential of a synthetic active pharmaceutical ingredient known as cannabidiol which is currently being studied for the treatment of epilepsy, pain, arthritis and schizophrenia amongst other indications. Botanix is preparing for the first human trials utilizing synthetic cannabidiol in a proprietary drug delivery system (Permetrex™) for direct skin delivery of the therapy.

announcement	t+2 movement	date
Botanix Announces Top Line BTX 1204 Atopic Dermatitis Data Periodic Reports · Market sensitive	-61.19%	24 Mar 2020
Trading Halt Stock Exchange Announcement · Market sensitive	-61.19%	23 Mar 2020
Antimicrobial Platform Update and Launch of BTX 1801 Study Periodic Reports · Market sensitive	-	12 Mar 2020
Cowen Conference and Additional BTX 1503 Data Analysis Periodic Reports	+13.16%	03 Mar 2020
Half Yearly Report and Accounts Periodic Reports · Market sensitive	-	27 Feb 2020
Change of Director's Interest Notice SW Shareholder Details	-6.98%	25 Feb 2020
Final Director's Interest Notice RT Shareholder Details	-1.15%	11 Feb 2020
Initial Director's Interest Notice MC Shareholder Details	-1.15%	11 Feb 2020
Botanix Board Update Company Administration	-	10 Feb 2020
Appendix 4C - Quarterly Commitments test entity quarterly reports · Market sensitive	-	30 Jan 2020
Rows per page: 1-10 of 254

Announcements

Market Data